MKGAF Stock UPDATES Merck Kgaa Dm 5 (MKGAF) 86.8600 10/22/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2014 at 6:55 PM

Merck Kgaa Dm 5 (MKGAF) 86.8600 $MKGAF

Sigma-Aldrich Offers Ascentis Express 2.0 Micron UHPLC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 3:00PM CDT
Sigma-Aldrich (SIAL) has launched Ascentis Express 2.0 micron built on Fused-Core particle design.
SIAL: 135.85 (+0.25), TROX: 22.61 (-0.69), FSI: 1.17 (-0.08)

Sigma-Aldrich to Acquire Cell Marque to Bolster IHC Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 11:30AM CDT
Sigma-Aldrich Corporation (SIAL) announced that it has agreed acquire Cell Marque Corporation in order to strengthen its diagnostic health capabilities.
GSM: 17.85 (-0.16), SIAL: 135.85 (+0.25), FSI: 1.17 (-0.08)

BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:24PM CDT
The FDA received paragraph IV certification notice pertaining to BioMarin's (BMRN) Kuvan.
ENDP: 63.19 (-0.54), BMRN: 74.32 (-0.39), AMGN: 143.64 (-0.45)

Merck KGaA Records the Largest Acquisition in Their History at $17 Billion (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 8:00AM CDT
Merck KGaA (MKGAF) will acquire Sigma-Aldrich for $17 billion, or $140 per share in cash.
SIAL: 135.85 (+0.25)

Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
BIIB: 309.07 (-17.70), GILD: 106.09 (-0.58), RGDO: 1.13 (-0.02)

Merck KGaA Teams Up with Sutro for ADCs Targeting Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 6:00PM CDT
Merck KGaA's (MKGAF) signed a collaboration and license agreement with Sutro Biopharma to develop antibody drug conjugates (ADCs) targeting cancer cells.
LCI: 44.72 (-0.24), AVNR: 11.66 (-0.13), SGEN: 34.83 (-0.48)

Merck KGaA-Lupin Ink Deal, Focus on Emerging Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:14PM CDT
Merck KGaA (MKGAF) entered into a partnership with Lupin Ltd. with the aim of expanding Merck KGaA's General Medicine & Endocrinology franchise in emerging markets.
LCI: 44.72 (-0.24), AVNR: 11.66 (-0.13), ANAC: 27.66 (-0.58)

Merck KGaA Stops All Tecemotide Studies for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:42PM CDT
Merck KGaA (MKGAF) stops all studies on tecemotide as a monotherapy for non-small cell lung cancer (NSCLC) and focuses on developing other candidates.
LCI: 44.72 (-0.24), AVNR: 11.66 (-0.13), ANAC: 27.66 (-0.58)

Merck KGaA's Kuvan Effective in Under-4 Year Olds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:35PM CDT
Merck KGaA (MKGAF) announced that Kuvan showed statistically significant 26-week data from the phase IIIb SPARK study in children (<4 years) with phenylketonuria.
LCI: 44.72 (-0.24), ENDP: 63.19 (-0.54), BMRN: 74.32 (-0.39)

Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
AGN: 182.81 (-3.35), MNK: 87.10 (-2.20), ENDP: 63.19 (-0.54)

Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:00AM CDT
Merck KGaA's (MKGAF) second-quarter 2014 earnings per American Depositary Receipt (ADR) came in at $1.52, down 1.8% from the year-ago quarter.
ENDP: 63.19 (-0.54), UTHR: 129.00 (+1.39), ANAC: 27.66 (-0.58)

Roche Collaborates with Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 5:30PM CDT
Roche's (RHHBY) Ventana Medical Systems announced that it has entered into an agreement with Germany-based Merck KGaA.
AZN: 68.78 (-0.22), ABBV: 56.90 (+0.61)

Merck KGaA-Mersana Therapeutics Strike a Deal on ADCs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 4:20PM CDT
Merck KGaA (MKGAF) inked a deal with Mersana Therapeutics for the development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer.
SGEN: 34.83 (-0.48), ARIA: 5.59 (-0.20)

Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641).
GILD: 106.09 (-0.58), ARIA: 5.59 (-0.20)

Merck KGaA & MorphoSys Sign Deal, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 3:30PM CDT
Merck KGaA (MKGAF) and MorphoSys inked a deal to discover and develop therapeutic antibodies against undisclosed immune checkpoints.
ANIP: 27.93 (-0.16), INCY: 52.47 (+0.03), AZN: 68.78 (-0.22)

Merck KGaA/Auxogyn's Eeva System Gets FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 3:40PM CDT
Merck KGaA's (MKGAF) biopharma division, Merck Serono, announced that the FDA has granted clearance to Merck KGaA and partner Auxogyn's Early Embryo Viability Assessment (Eeva) System.
Q: 56.55 (+0.05), GILD: 106.09 (-0.58), ANIP: 27.93 (-0.16)

Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
LCI: 44.72 (-0.24), ACT: 231.41 (-0.72), SLXP: 137.61 (-2.94)

Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.
LCI: 44.72 (-0.24), ACT: 231.41 (-0.72), FRX: 99.00 (-0.77)

Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
ECYT: 5.63 (+0.05), AVNR: 11.66 (-0.13), BIOD: 1.39 (-0.05)

Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.
BIIB: 309.07 (-17.70), THLD: 2.97 (-0.03), LLY: 64.68 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Krispy Kreme Faces Legal Heat Post McDonald's Exit

Krispy Kreme's Sugar-Coated Trouble Ah, Krispy Kreme, where donuts and legal woes seem to go hand in hand these days. Dropping donuts might be a morning mishap, but dropping a stock by 37%? Now that’s a disaster, especially when folks like Schubert Jonckheer & Kolbe smell a rat in the kitchen. Fresh Out of the Baker's Oven: Lawsuit Updates On August 26, 2026, a...

Paratus Energy Lands Petrobras Tender, Ties Finalizing

Seagems Joint Venture Snags Petrobras Contract Let’s dive headfirst into this business update, because this one's got teeth, folks. Petrobras, the big dog in Brazil’s oil arena, has given the green light to Seagems’ bid, a joint venture half-owned by Paratus Energy Services Ltd. The target? A hefty pipe-laying support vessel (PLSV) contract starting in 2028. But...

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

Specialty1 Partners: Top Workplaces Triumph in 2026

Employees Crown Specialty1 Partners a Workplace Gem There are only a few things in the business world sweeter than being named a Top Workplace, and flying that banner proudly is exactly what Specialty1 Partners gets to do. Named a winner by the Houston Chronicle in 2026, this recognition is no regular accolade. It's built on the raw honesty that employee surveys provide,...

SoCalGas Fuels Community Cleanup of Public Lands

As Southern Californians gear up for another sun-drenched November, volunteering to clean and care for public lands might not be top of mind—yet that's exactly what they're being invited to embrace. Thanks to a stout $50,000 contribution from Southern California Gas Company (SoCalGas), under the umbrella of Sempra (NYSE: SRE), there's a real chance to make a difference...

Black Farmers Revitalize Birmingham with Historic Market

A Bold Return to Roots in Fountain Heights Fountain Heights, Birmingham—a place that's been screaming for change, finally gets its answer. Imagine, for almost 70 years, not a single grocery store in the neighborhood. That’s as wild as it gets. Streets once echoing with challenges now buzz with a new beginning. Enter the We All Eat Market by Fountain Heights Farms...

Formation Unveils First Solana Tokenized Securities Venue

Well, here we go. Formation Securities is setting sail on the high seas of blockchain, aiming to operate a tokenized securities venue (TSV) on Solana. This isn't your garden-variety launch—it's a bold leap into a newer, faster-paced world of trading. Sure, you’ve heard about blockchains before, but this operation marries the traditional rigmarole of the stock market...

ABYSS Revolutionizes Infrastructure Management with New Tech

Pioneering Transformation in Infrastructure Management Ever felt like infrastructure management's been stuck in the stone age? Well, Houston's own ABYSS just kicked that notion to the curb. Formerly Abyss Solutions, they're relaunching themselves with a new mission that might just set the industry on fire. They're calling it the Asset Operating Environment, and trust me,...

Cohen & Steers Sees Steady Rise in October AUM

Market Pushes Cohen & Steers Forward It's been a wild ride for financial managers lately, and Cohen & Steers, Inc. (NYSE: CNS) isn't exempt from the rollercoaster. As of October 31, 2026, they've reported assets under management (AUM) climbing to $99.6 billion—thanks to a hefty market appreciation of $4 billion. Not too shabby when you're dealing with the...

AI Faces Accountability Trials in Business 2027

Charting the AI Accountability Course In 2027, the corporate AI landscape won't be the Wild West anymore; it's morphing into a structured battlefield where the winners will be those who successfully enforce accountability. The hands-off, carte blanche days of AI are fading fast, and businesses are starting to scrutinize the AI tools they've been throwing money at. "The...